Boehringer Ingelheim and Veeva Unveil Revolutionary One Medicine Platform

Boehringer Ingelheim and Veeva Systems Collaborate on One Medicine Platform

Boehringer Ingelheim, a leading biopharmaceutical company, has officially launched its groundbreaking platform called One Medicine, in partnership with Veeva Systems (NYSE: VEEV). Announced on March 11, 2025, this initiative is a significant step toward modernizing clinical trial processes and expediting the development of treatments for previously untreatable diseases.

The foundation of this innovative platform is built on the successful implementation of the Veeva Development Cloud, which was first announced in March 2022. The One Medicine platform combines clinical, regulatory, and quality data into a unified system, which allows for smoother integration across various functions within Boehringer. As a result, the company is expected to enhance the efficiency of clinical trials and improve collaboration with research sites.

Oliver Fink, Boehringer's head of learning, processes, and digitization, stated, “With Veeva, Boehringer has advanced its approach to clinical trials and is committed to accelerating access to innovative and life-changing treatments for patients worldwide.” He emphasized that the Veeva Development Cloud provides the technological backbone necessary for teams to design and execute studies more swiftly, effectively, and in compliance with regulatory standards.

Rik van Mol, Senior Vice President at Veeva, remarked, “By connecting clinical, regulatory, and quality services via the Veeva Development Cloud, Boehringer is breaking down silos between teams. This integration is a pivotal development in advancing the shared mission of Veeva and Boehringer to leverage data and technology to modernize clinical trials for improved patient outcomes.”

The One Medicine platform aims to revolutionize how pharmaceutical products are developed. By consolidating applications for clinical, quality, regulatory, and safety processes, it simplifies end-to-end business processes and promotes operational excellence.

As health needs become increasingly complex, both companies recognize the importance of adaptability in research and drug development. Boehringer Ingelheim has a long-standing reputation as a significant player in healthcare, not only focusing on innovative therapies but also emphasizing sustainable practices throughout its operations. Founded in 1885, the company operates independently and prioritizes rigorous research and development, pooling efforts from its over 53,500 employees across more than 130 markets.

On the other hand, Veeva Systems has carved out a niche as a leader in cloud-based software specifically designed for the life sciences industry. The company serves over 1,000 clients, ranging from large global biopharmaceutical entities to emerging biotech firms. Veeva is committed to balancing the interests of all its stakeholders, including customers, employees, shareholders, and the healthcare community.

In a future where healthcare innovation is crucial, the partnership between Boehringer Ingelheim and Veeva marks a historic milestone. The One Medicine platform is poised to address urgent medical needs more efficiently, accelerating the arrival of necessary treatments to those who need them.

For more information about Veeva Development Cloud, you can visit their website at veeva.com/DevelopmentCloud. For details about Boehringer Ingelheim, check boehringer-ingelheim.com.

Both companies continue to focus on pushing the boundaries of what is possible in pharmaceutical innovation, ensuring that patients around the world benefit from cutting-edge medical advancements.